

Erasmus MC  
Universitair Medisch Centrum Rotterdam

Cancer Institute



## *Mild Hyperthermia in Cancer Therapy*

Gerard C. van Rhoon  
g.c.vanrhoon@erasmusmc.nl



# Disclosure of potential conflict of interest

- 1. Employment or Leadership Position**
  - **Erasmus MC Cancer Institute, Rotterdam**
- 2. Advisory Role or Expert Testimony**
  - **Health Council of the Netherlands**
  - **President of the European Society for Hyperthermic Oncology**
- 3. Stock Ownership**
  - **none of the companies mentioned**
- 4. Patent, Copyright, Licensing**
  - **Erasmus MC Daniel den Hoed Cancer Center, Rotterdam**
- 5. Honoraria**
  - **Speag, Sennewald Medizintechnik**
- 6. Financing of Scientific Research**
  - **Koningin Wilhelmina Foundation (Dutch Cancer Society)**
  - **Technology Foundation STW, Netherlands Organization for Health Research and Development,**
  - **Erasmus MC Friends Foundation**
- 7. Other Financial Relationships**
  - **none**



# Definitions for heating tissue



**Hyperthermia (mild):** Mild Temperatures 40-44°C  
Duration: 60-90 min  
Multiple (4-6) fraction

**Thermal Ablation:** High Temperatures >65 °C  
Short duration: 5-15 min  
Single fraction


**Direct Cell Kill**

# ***Hyperthermia Works!!***


***Biology: hyperthermia is one of the strongest sensitizers for radiotherapy and chemotherapy***



# Hyperthermia Amplifies Radiation and Drugs



**Sequential application of Hyperthermia to Radiotherapy:  
Objective enhance local controle**



***Impact of sequence & time interval of radiotherapy and hyperthermia on sensitization effect***

# Hyperthermia Works!!

**Biology: hyperthermia is one of the strongest sensitizers for radiotherapy and chemotherapy**

**Has been shown beneficial for patients with**

- **advanced tumors**
- **recurrent tumors in previously irradiated areas**
  
- **24 positive randomized trails RT or CT  $\pm$  HT**
- **10 inconclusive randomized trails on RT or CT  $\pm$  HT (many of those criticized for low quality of heating)**


Author	Year	Tumor	Modality	Local	HT	HT/RT
Blanchard (1985)	85	Thyroid cancer	RT	50	50%	50%
Blanchard (1986)	86	Thyroid cancer	RT	70	50%	50%
Blanchard (1987)	87	Thyroid cancer	RT	50	50%	50%
Blanchard (1988)	88	Thyroid cancer	RT	50	50%	50%
Blanchard (1989)	89	Thyroid cancer	RT	50	50%	50%
Blanchard (1990)	90	Thyroid cancer	RT	50	50%	50%
Blanchard (1991)	91	Thyroid cancer	RT	50	50%	50%
Blanchard (1992)	92	Thyroid cancer	RT	50	50%	50%
Blanchard (1993)	93	Thyroid cancer	RT	50	50%	50%
Blanchard (1994)	94	Thyroid cancer	RT	50	50%	50%
Blanchard (1995)	95	Thyroid cancer	RT	50	50%	50%
Blanchard (1996)	96	Thyroid cancer	RT	50	50%	50%
Blanchard (1997)	97	Thyroid cancer	RT	50	50%	50%
Blanchard (1998)	98	Thyroid cancer	RT	50	50%	50%
Blanchard (1999)	99	Thyroid cancer	RT	50	50%	50%
Blanchard (2000)	00	Thyroid cancer	RT	50	50%	50%
Blanchard (2001)	01	Thyroid cancer	RT	50	50%	50%
Blanchard (2002)	02	Thyroid cancer	RT	50	50%	50%
Blanchard (2003)	03	Thyroid cancer	RT	50	50%	50%
Blanchard (2004)	04	Thyroid cancer	RT	50	50%	50%
Blanchard (2005)	05	Thyroid cancer	RT	50	50%	50%
Blanchard (2006)	06	Thyroid cancer	RT	50	50%	50%
Blanchard (2007)	07	Thyroid cancer	RT	50	50%	50%
Blanchard (2008)	08	Thyroid cancer	RT	50	50%	50%
Blanchard (2009)	09	Thyroid cancer	RT	50	50%	50%
Blanchard (2010)	10	Thyroid cancer	RT	50	50%	50%
Blanchard (2011)	11	Thyroid cancer	RT	50	50%	50%
Blanchard (2012)	12	Thyroid cancer	RT	50	50%	50%
Blanchard (2013)	13	Thyroid cancer	RT	50	50%	50%
Blanchard (2014)	14	Thyroid cancer	RT	50	50%	50%
Blanchard (2015)	15	Thyroid cancer	RT	50	50%	50%
Blanchard (2016)	16	Thyroid cancer	RT	50	50%	50%
Blanchard (2017)	17	Thyroid cancer	RT	50	50%	50%
Blanchard (2018)	18	Thyroid cancer	RT	50	50%	50%
Blanchard (2019)	19	Thyroid cancer	RT	50	50%	50%
Blanchard (2020)	20	Thyroid cancer	RT	50	50%	50%
Blanchard (2021)	21	Thyroid cancer	RT	50	50%	50%
Blanchard (2022)	22	Thyroid cancer	RT	50	50%	50%
Blanchard (2023)	23	Thyroid cancer	RT	50	50%	50%
Blanchard (2024)	24	Thyroid cancer	RT	50	50%	50%



# THE LANCET Oncology

## Inoperable melanoma


J. Overgaard et al.  
Lancet 1995; 540-3



## local advanced cervical cancer


Van der Zee et al. Lancet 2000;355:1119

Cervix 3-yrs overall survival  
27% → 51%



## localised high-risk soft-tissue sarcoma

Issels et al., Lancet Oncology 2010, 561-70





# Hyperthermia Works!!


**Biology: hyperthermia is one of the strongest sensitizers for radiotherapy and chemotherapy**

**Has been shown beneficial for patients with**

- **advanced tumors**
- **recurrent tumors in previously irradiated areas**
- **24 positive randomized trails RT or CT  $\pm$  HT**
- **10 inconclusive randomized trails on RT or CT  $\pm$  HT (many of those criticized for low quality of heating)**
- **In most trials: hyperthermia does not enhance late toxicity**
- **Clinical experience that it can be applied to frail elderly people (who are excluded for surgery or intolerant for chemotherapy)**

Author	Year	Tumor	Modality	Local	HT	HT+RT
Wang 1984	80	Thyroid cancer	RT	50	50%	50%
Wang 1985	85	Thyroid cancer	RT	50	50%	50%
Wang 1986	86	Thyroid cancer	RT	50	50%	50%
Wang 1987	87	Thyroid cancer	RT	50	50%	50%
Wang 1988	88	Thyroid cancer	RT	50	50%	50%
Wang 1989	89	Thyroid cancer	RT	50	50%	50%
Wang 1990	90	Thyroid cancer	RT	50	50%	50%
Wang 1991	91	Thyroid cancer	RT	50	50%	50%
Wang 1992	92	Thyroid cancer	RT	50	50%	50%
Wang 1993	93	Thyroid cancer	RT	50	50%	50%
Wang 1994	94	Thyroid cancer	RT	50	50%	50%
Wang 1995	95	Thyroid cancer	RT	50	50%	50%
Wang 1996	96	Thyroid cancer	RT	50	50%	50%
Wang 1997	97	Thyroid cancer	RT	50	50%	50%
Wang 1998	98	Thyroid cancer	RT	50	50%	50%
Wang 1999	99	Thyroid cancer	RT	50	50%	50%
Wang 2000	00	Thyroid cancer	RT	50	50%	50%
Wang 2001	01	Thyroid cancer	RT	50	50%	50%
Wang 2002	02	Thyroid cancer	RT	50	50%	50%
Wang 2003	03	Thyroid cancer	RT	50	50%	50%
Wang 2004	04	Thyroid cancer	RT	50	50%	50%
Wang 2005	05	Thyroid cancer	RT	50	50%	50%
Wang 2006	06	Thyroid cancer	RT	50	50%	50%
Wang 2007	07	Thyroid cancer	RT	50	50%	50%
Wang 2008	08	Thyroid cancer	RT	50	50%	50%
Wang 2009	09	Thyroid cancer	RT	50	50%	50%
Wang 2010	10	Thyroid cancer	RT	50	50%	50%
Wang 2011	11	Thyroid cancer	RT	50	50%	50%
Wang 2012	12	Thyroid cancer	RT	50	50%	50%
Wang 2013	13	Thyroid cancer	RT	50	50%	50%
Wang 2014	14	Thyroid cancer	RT	50	50%	50%
Wang 2015	15	Thyroid cancer	RT	50	50%	50%
Wang 2016	16	Thyroid cancer	RT	50	50%	50%
Wang 2017	17	Thyroid cancer	RT	50	50%	50%
Wang 2018	18	Thyroid cancer	RT	50	50%	50%
Wang 2019	19	Thyroid cancer	RT	50	50%	50%
Wang 2020	20	Thyroid cancer	RT	50	50%	50%
Wang 2021	21	Thyroid cancer	RT	50	50%	50%
Wang 2022	22	Thyroid cancer	RT	50	50%	50%
Wang 2023	23	Thyroid cancer	RT	50	50%	50%
Wang 2024	24	Thyroid cancer	RT	50	50%	50%

# Most common techniques to induce hyperthermia use electromagnetic energy



Other technologies used, are:

- Ultrasound
- Infrared
- Laser
- Magnetic nano-particles

# Hyperthermie systemen Erasmus MC


**Superficial Hyperthermia:**  
 tumors up to 4 cm depth.



**Loco regional hyperthermia:**  
 Tumor locations in Head and Neck region






**Regional deep hyperthermia:**  
 Tumor locations at depths > 4cm, i.e. Pelvis, thorax.



# Energy steering to obtain optimal heating

*Erasmus*



*Focused energy deposition at depth: circumferential EM field, constructive interference.*


## *Main challenges*

- *Measure temperature at depth*
- *Target energy to the tumor*
- *Prevent acute thermal toxicity*
  
- *Solutions have been implemented during last decennium.*

# Thermal dose effect relationships indicate the need to maximize tumor temperature

## Thermal dose effect relationship


*Franckena et al., 2009 European J Cancer*



**Of 444 patient, 40% showed a positive correlation between T50 and applied energy.**


*Fatehi et al., 2007, Int. J. of Hyperthermia*

## Online Complaint adaptive SAR steering using VEDO



# Hyperthermia Treatment Planning (HTP): an essential part for optimal treatment delivery

Erasmus MC Cancer Institute



## Workflow




# VEDO is an online HTP-GUI to guide energy steering during actual treatment delivery



**VEDO**

Visualization tool for  
Electromagnetic field and  
Dosimetry  
Optimization






# VEDO is an online HTP-GUI to guide energy steering during actual treatment delivery



**VEDO**

Visualization tool for  
Electromagnetic field and  
Dosimetry  
Optimization





# Clinical experience from hyperthermia

- *The human body has an efficient physiological defense mechanism to limit temperature increase under thermal stress (despite a high RF-power input it is hard to increase the average temperature)*

**Variable thermal regulation response within a patient after a deep hyperthermia treatment for 90 minutes at 40-42 °C**



# Clinical experience from hyperthermia

- ***The human body has an efficient physiological defense mechanism to limit temperature increase under thermal stress (despite a high RF-power input it is hard to increase the average temperature)***
- ***High temperatures at the skin are sensed as burning pain***
- ***High temperatures at depth are sensed as pressure pain, urging, period pain, etc.***
- ***Responding to pain complaints can adequately confine thermal toxicity***
- ***Areas with reduced sensitivity have a high risk for burns (skars have also a reduced perfusion making them extra vulnerable to thermal damage)***
-

# Loco-regional deep heating Typical values


RF-power and temperature data analysis of 444 patients with primary cervical cancer

Fatehi et al., 2007 , Int. J. of Hyperthermia



Whole body SAR for therapeutic temperatures: 9-10 ( $\pm 2$ ) W/kg  
 Max. Forward power applied: 768-934 ( $\pm 185$ ) W

More power is needed for heavier patients though average temperature is lower.



Three weight groups

# Acute hyperthermia toxicity to subcutaneous tissue

Grade	Description	Number
0	No symptoms	267
1	Symptoms lasting less than 3 days	80
2	Symptoms lasting 3-14 days	60
3	Symptoms lasting 3-14 days, or causing a delay or interruption of treatment	16
4	Symptoms requiring surgery	1



Patients with toxicity had:

- thicker (0.7 cm) dorsal subcutaneous fat
- were larger in anterior-posterior (0.9 cm) and lateral (1.5 cm) directions.



After adjustment for these factors, only the average intraluminal TRISE increase correlated with toxicity probability (TRISE 1.7 °C higher,  $p = 0.010$ )

Five patients developed grade 3 neurotoxicity


# Location complaints matches with predicted location hot-spot



# Location complaints matches with predicted location hot-spot




Closest HS in model



*~90% of complaints have a predicted hotspot in the same region as the actual complaint*

# No clear relation between max SAR values (10ml) during treatment and complaints



○ No complaints   ○ Complaints   ○ Toxicity





# HT treatment planning

overview



Erasmus MC

Cancer Institute



CT scan

~200 slices




segmentation

Patient model



Applicator model



EM simulation & optimization

T simulation & optimization


Purposes: decision making, optimization, analyses

# HT treatment planning

overview

ErasmusMC



Cancer Institute




Purposes: decision making, optimization

# Induced psSAR in the brain: Influence of brain tissue segmentation


- Segmentation details:



*Brain exposure decreases in detailed model compared to homogeneous model by 21.5%*



# Induced psSAR in the brain (10 g)



# HT-related acute health effect

- Common Toxicity Criteria (CTC) is a standardized classification of adverse effects used in cancer therapy evaluation, developed by National Cancer Institute.

### *CTC Grades definition:*

Grade	Definition
1	Mild adverse event; asymptomatic or mild symptoms; Clinical or diagnostic observations only; intervention not indicated.
2	Moderate adverse event; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL*.
3	Severe or medically significant but not immediately life-threatening; Hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL**.
4	Life-threatening consequences; urgent intervention indicated.
5	Death related to adverse event

*Activities of Daily Living (ADL)*

\**Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.*

\*\**Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.*

# Observed acute toxicity for the 16 selected patients


**Table 3.** Observed acute toxicity for the selected HT patients. Note that the number of incidents were counted, i.e. not just one incident per patient, so every treatment session always led to one score.

		Nr of patients: 16 Total Nr of HT sessions:74					
CTC-grade		0	1	2	3	4	5
CNS-related	Pns motory	74	0	0	0	0	0
	Pns sensory	71	1	2	0	0	0
	Headache	73	1	0	0	0	0
	Pain in Eye	73	1	0	0	0	0
	Dizziness	73	1	0	0	0	0
	Nausea <sup>a</sup>	71	2	1	0	0	0
	Vo miting <sup>a</sup>	72	2	0	0	0	0
Subcut burns	Subcut skin	70	2	0	2	0	0
	Subcut fat	72	0	2	0	0	0
	Subcut muscle	72	0	2	0	0	0
	Subcut bone	69	1	3	1	0	0

<sup>a</sup> Nausea and vomiting may stem from reactions in the CNS but also from many other causes. In this study they are considered as CNS-related acute effects.

# Observed acute toxicity for the 16 selected patients versus psSAR

Adibzadeh F., PMB, 2015



Evaluation of acute adverse effects from prolonged exposure to deep RF head and neck hyperthermia reveals that although the brain was exposed up to 14 times the common basic restriction on psSAR10g, there is no indication of any induced serious neurological adverse effect. This study provides initial data that enables to determine the basic restrictions based on the functional change that is to be prevented and the level of safety to ensure prevention.

# Temperature simulations in hyperthermia treatment planning of the head and neck region: Rigorous optimization of tissue properties

Verhaart R, *Strahlenther Onkol* 2014

**Table 3** Literature values for baseline [13–16] and thermal stress [17], as well as the optimized patient group values from this study for perfusion ( $\omega$ ) and thermal conductivity ( $k$ ) in tumor, muscle, and fat tissue

	$\omega_{\text{Tumor}}$	$\omega_{\text{Muscle}}$	$\omega_{\text{Fat}}$	$k_{\text{Tumor}}$	$k_{\text{Muscle}}$	$k_{\text{Fat}}$
	[ml min <sup>-1</sup> kg <sup>-1</sup> ]	[W m <sup>-1</sup> °C <sup>-1</sup> ]		[W m <sup>-1</sup> °C <sup>-1</sup> ]		
Literature: baseline	400.0	39.1	32.7	0.51	0.49	0.21
Literature: thermal stress	80.0	300.0	200.0	0.64	0.64	0.21
Optimized (this study)	1146.0	563.6	76.7	0.97	5.75	0.38

*Perfusion ( $\omega$ ) and thermal conductivity ( $k$ ) were simultaneously optimized for muscle, fat, and tumor by minimizing the cumulative error between measured and simulated temperature points at steady state Temperature ( $T_{ss}$ ) in a group of 17 patients.*



## Summary

*Hyperthermia is valuable adjuvant to radiotherapy and chemotherapy in the treatment of cancer.*

*Toxicity associated with hyperthermia is mainly acute and consists of thermal burns, mostly of grade 1-2.*

*The high energy exposure levels of EMF for hyperthermia can be informative for potential assessment of threshold levels for EMF effects in critical tissues, such as brain, as this is one of the few occasions where human tissue is exposed above the ICNIRP guidelines.*

*First analysis of such human data have not shown adverse, acute effects at levels 14 times of the common basic restriction guideline of ICNIRP.*

# Acknowledgements.

*Dept. of Radiation Oncology  
- Radiation Oncologists*

[www.erasmusmc.nl/radiotherapie](http://www.erasmusmc.nl/radiotherapie)

*Members of the Rotterdam  
Hyperthermia group*

*Dr. Sennewald Medizin Technik Gmbh,  
Munich, Germany*

*TNO-FEL Netherlands*

*ITIS & Speag, Zurich, Swiss*

*Dutch National Aerospace labororium*

*Hyperthermia Groups of*

- Berlin
- Utrecht
- Amsterdam
- Duke
- San Francisco



## Sponsors

Koningin Wilhelmina Fonds/ Dutch  
Cancer Society



Technology Foundation STW



Maurits and Anna de Kock  
Foundation

Stichting Bevorderings Volkskracht  
Rotterdam

Nijbakker-Mora Stichting

Dutch National Aerospace  
Laboratory